Durvalumab alone or in combination with bevacizumab for HCC after curative resection or ablation - Clinical Trial
What is the Purpose of this Study?
We are doing this study to see if the study drug durvalumab, either alone or with bevacizumab, can be used to prevent the return of hepatocellular carcinoma.
Who Can Participate in the Study?
Adults with hepatocellular carcinoma who:
-Had their hepatocellular carcinoma recently treated with surgery or ablation; and
-Are considered to be at a high risk of recurrence.
What is Involved?
If you choose to join this study, you will:
-Be randomly assigned (like drawing names from a hat) to 1 of 3 groups:
---Group A will get the study drugs durvalumab and bevacizumab
---Group B will get durvalumab and a placebo (harmless saline)
---Group C will get placebos instead of both drugs
Both Groups will:
-Get their treatment through an I.V. once every 3 weeks for 1 year.
-Give blood and urine samples during their clinic visits
-Have regular CT or MRI scans done to see if their cancer has returned